About Inhibrx Biosciences, Inc. - Common Stock (INBX)
Inhibrx Biosciences Inc is a biotechnology company focused on the discovery and development of innovative therapeutic solutions for patients with cancer and other serious diseases. The company employs its proprietary platform to engineer novel protein-based therapeutics that target specific disease mechanisms, aiming to enhance the efficacy and safety of treatments. Through rigorous research and clinical trials, Inhibrx seeks to advance its drug candidates, offering hope for new options in the ever-evolving landscape of medical therapies. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading strengthened market conviction that the Federal Reserve will cut interest rates by 25 basis points at its Oct. 30 policy meeting.
San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly positive topline results from its registrational trial of ozekibart (INBRX-109) for advanced or metastatic, unresectable chondrosarcoma. This monumental achievement positions ozekibart as a potential
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Inhibrx Biosciences shares surged nearly 76% in after-hours trading Thursday after the company reported positive Phase 2 trial results for its cancer drug Ozekibart.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc. (NasdaqGM: INBX) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Inhibrx will receive $30.00 in cash, a contingent value right of $5.00 (conditioned upon the achievement of a regulatory milestone), and 0.25 shares of a new publicly traded company that will retain Inhibrx’s non-INBRX-101 assets, for each share of Inhibrx that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
